Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2026 09:30 ET | Source: LIfT BioSciences

LIfT BioSciences Announces Publication of Review Article in Frontiers in Immunology Highlighting Broad Therapeutic Potential of Neutrophils and IMANs in Cancer

Neutrophils, long considered short-lived immune cells, can be therapeutically targeted when their appropriate subset and functional state are identified for the disease contextLIfT BioSciences’...
April 22, 2026 07:00 ET | Source: EvolveImmune Therapeutics

EvolveImmune Therapeutics Highlights Progress for Lead Asset EVOLVE104 and EVOLVE T Cell Engager Platform in Multiple Presentations at 2026 AACR Annual Meeting

Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to Plan Oral Minisymposium Presentation Demonstrates That EVOLVE T Cell Engagers Drive Greater T Cell Activation, Proliferation and...
April 21, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026

SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) – Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company...
April 21, 2026 04:27 ET | Source: Research and Markets

Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - Size, Regulatory Approvals, Proprietary Technologies, Therapeutic Applications

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Targeted Alpha Therapy Market Size, Regulatory Approvals, Proprietary Technologies, Therapeutic Applications & Clinical Trials Insight 2030"...
April 21, 2026 04:14 ET | Source: Research and Markets

Oncolytic Virus Immunotherapy Market Landscape Report 2026: A $5 Opportunity by 2031 - Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insights

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Oncolytic Virus Immunotherapy Market Opportunity, Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insight 2031" report has...
April 21, 2026 04:13 ET | Source: Research and Markets

Trispecific Antibodies Market Landscape Report 2026: Opportunity and Proprietary Insights - 90 Trispecific Antibodies by Company, Country, Indication & Phase

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Trispecific Antibodies Market Opportunity, Proprietary Technologies & Clinical Trials Insight 2026" report has been added to ...
April 20, 2026 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
April 20, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
April 19, 2026 18:00 ET | Source: Immunocore Holdings plc

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with...
April 14, 2026 07:00 ET | Source: EvolveImmune Therapeutics

EvolveImmune Therapeutics to Present Update on Lead Asset EVOLVE104 and New Data for EVOLVE T Cell Engager Platform at 2026 AACR Annual Meeting

Poster Presentation to Spotlight Ongoing Phase 1 Clinical Trial of EVOLVE104 Oral and Poster Presentations to Highlight Preclinical Data Demonstrating Ability of EVOLVE Platform to Drive Enhanced T...